To investigate the predictive value of neuron-specific enolase (NSE) on intensive care unit (ICU) mortality in patients with septic shock. Seventy-five patients with septic shock hospitalized in the emergency intensive care unit (EICU) of Hebei General Hospital from March 2020 to September 2021 were included, and the patients’ baseline characteristics and laboratory findings were collected. NSE levels on the first and fourth days after admission were retrieved. NSE% [(NSEday1 – NSEday4)/NSEday1 × 100%] and δNSE (NSEday1 – NSEday4) were calculated. The outcome indicator was ICU mortality. The patients were divided into the survivors group (n = 57) and the nonsurvivors group (n = 18). Multivariate analysis was performed to assess the relationship between NSE and ICU mortality. The predictive value of NSE was evaluated using receiver operating characteristic (ROC) curve. There were no significant differences in age, gender, systolic blood pressure (SBP), heart rate (HR), acute physiology and chronic health evaluation II score (APACHE II score), source of infection, and comorbidities between the 2 groups (all P > .05). Interleukin-6 (IL-6), NSE (day1), and NSE (day4) were significantly higher in patients in the nonsurvivors group (all P < .05), and there were no statistical differences in other laboratory tests between the 2 groups (all P > .05). APACHE II score, IL-6, lactate (Lac), total bilirubin (TBil), NSE (day1), and NSE (day4) showed a weak positive correlation with ICU mortality in patients with septic shock (all P < .05). Multivariate logistic regression analysis demonstrated that APACHE II score (odds ratio [OR] = 1.166, 95% confidence interval [95% confidence interval [CI]] 1.005–1.352, P = .042), IL-6 (OR = 1.001, 95% CI 1.000–1.001, P = .003) and NSE (day4) (OR = 1.099, 95% CI 1.027–1.176, P = .006) were independently associated with the ICU mortality of sepsis shock patients. The area under the curve (AUCs) of APACHE II score, IL-6, NSE (day1), and NSE (day4) for predicting prognosis were 0.650, 0.694, 0.758 and 0.770, respectively (all P < .05). NSE(day4) displayed good sensitivity and specificity (Sn = 61.11%, Sp = 91.23%) for predicting ICU mortality with a cutoff value of 25.94 ug/L. High-level NSE (day4) is an independent predictor of ICU mortality in sepsis shock patients, which may become a good alternate option for evaluating sepsis severity. More extensive studies are needed in the future to demonstrate the prognosis value of NSE.
Background: The prognosis of obstructive colorectal cancer (oCRC) is worse than non-obstructive CRC, but the individualized prediction model for the prognosis of oCRC patients has not been established. The aim of this study was to select prognostic predictors to built a Nomogram model to predic the prognosis of oCRC patients. Methods: A retrospective study was conducted on 181 oCRC partients between February 2012 to December 2017 from three medical hospitals. 129 patients in one of the hospitals were assigned to the training chort.Univariate and multivariate analysis were used to select independent prognostic indicators in a training cohort and a Nomogram model was constructed. 52 patients foom another two hospital were used as the testing cohort to validate the model.Results: Multivariate analysis illustrated the CEA [p=0.037, HR=2.872 (1.065-7.740)], N stage [N1 vs. N0, p=0.028, HR=3.187 (1.137-8.938) ; N2 vs. N0, p=0.010, HR=4.098 (1.393-12.051)] and surgical procedure [p=0.002, HR=0.299 (0.139-0.643)] were independent prognostic factors for OS of oCRC patients. These factors were used to construct the Nomogram model. Both internal and external validation shows it relatively accuracy.Conclusions: CEA, N stage and surgical procedure were independent prognostic factors for OS of oCRC patients, Which can be visually exhibited by Nomogram model.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.